Latest Biotech News

Royalty Pharma struck a major royalty acquisition tied to Neurimmune’s cliramitug, paying $125 million upfront plus $125 million due in Q1 2027 and up to $175 million in milestone cash depending...

Scribe Therapeutics completed an upsized IPO targeting $129 million in gross proceeds, positioning the CRISPR-founded company to advance its in vivo gene-silencing pipeline beyond rare disease...

Scribe Therapeutics kicked off the second-half IPO window with a rare gene editing listing priced above earlier expectations. The company’s offering comes after more than two years without new...

Eli Lilly said it is positioned to file a Biologics License Application for retatrutide after additional Phase 3 obesity results cleared two more late-stage studies. The program, often described...

An FDA advisory panel narrowly recommended expanding access to compounded, unapproved peptides including BPC-157 and KPV, a decision that would loosen restrictions for patients and compound...

The National Institutes of Health launched Bio Genesis Mission to use artificial intelligence to accelerate biomedical research, framed as an effort nested inside Genesis Mission created under a...

Dassault Systèmes agreed to buy Arisglobal for up to $2 billion, aiming to consolidate fragmented life-sciences data and strengthen its bid to build a unified AI intelligence platform. The deal...

GSK received FDA approval for Jideytro (zidesamtinib), marking early payback on its $10.6 billion acquisition of Nuvalent completed last week. The approval covers adults with locally advanced or...

Sartorius disclosed revenue pressure tied to U.S. tariff refunds, saying it reduced revenue by €26 million to reflect refunds paid back to customers after Supreme Court action blocked parts of...

Samsung Biologics proposed an all-cash tender offer of about $1.8 billion for Switzerland-based PolyPeptide Group, aiming to expand its contract manufacturing capabilities beyond antibodies and...

An FDA advisory panel narrowly recommended expanding access to compounded, unapproved peptides, endorsing broader use of four products despite objections from scientists and concerns about the...

Eli Lilly reported two additional Phase 3 obesity results for retatrutide (its “triple-G” program) covering patients with type 2 diabetes and cardiovascular complications. The new top-line...

GSK’s recently acquired Nuvalent asset, zidesamtinib (branded Jideytro), received FDA approval in ROS1-positive metastatic non-small-cell lung cancer for adults previously treated with a ROS1...

Arrowhead Pharmaceuticals delivered positive Phase 3 results for plozasiran (Redemplo) in severe hypertriglyceridemia, setting up a supplemental NDA filing with the FDA before year-end. The...

NIH’s 4D Nucleome program issued a new set of studies describing how chromatin structure and DNA methylation shape gene regulation across tissues and disease states. The updated wave of...

Two new single-cell multi-omics efforts provided direct links between epigenetic architecture and gene regulation. Salk Institute and Arc Institute researchers reported a body-wide single-cell...

Samsung Biologics moved deeper into peptide therapeutics by proposing an all-cash tender offer for Switzerland-based PolyPeptide Group, a CDMO specializing in peptide-based APIs. The deal values...

Crystalys Therapeutics raised an oversubscribed $130 million Series B to accelerate dotinurad through Phase 3 registration-directed trials and commercialization preparation. The round is intended...

ABL Diagnostics agreed to buy French viral safety and bioassay services company Texcell for €2.9 million, pending transaction completion. The acquisition, cleared by a French commercial court,...

An international Phase 3 trial reported that daraxonrasib (an oral RAS(ON) multiselective tri-complex inhibitor) improved overall survival and progression-free survival versus...